CN Patent

CN110225767B — 细胞内atp增强剂

Assigned to StaGen Co Ltd · Expires 2021-11-26 · 4y expired

What this patent protects

本发明要解决的问题是提供具有增加细胞内ATP的效果的物质，和特别地远超过单独使用的肌苷或黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂的增加效果的强力ATP增强剂。人类或动物的细胞内ATP增强剂，其含有A)和B)的组合：A)黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂；和B)次黄嘌呤、或能够在体内转化为次黄嘌呤的化合物。

USPTO Abstract

本发明要解决的问题是提供具有增加细胞内ATP的效果的物质，和特别地远超过单独使用的肌苷或黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂的增加效果的强力ATP增强剂。人类或动物的细胞内ATP增强剂，其含有A)和B)的组合：A)黄嘌呤氧化酶/黄嘌呤脱氢酶抑制剂；和B)次黄嘌呤、或能够在体内转化为次黄嘌呤的化合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN110225767B
Jurisdiction
CN
Classification
—
Expires
2021-11-26
Drug substance claim
No
Drug product claim
No
Assignee
StaGen Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.